Apartment Investment and Management Co vs Alnylam Pharmaceuticals, Inc. — how do they compare? Apartment Investment and Management Co trades at $2.61 (market cap $376.16M), while Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.60B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 78.7× Apartment Investment and Management Co's market cap. Which is the better fit depends on your goals.
| AIV | ALNY | |
|---|---|---|
Market Cap | $376.16M | $29.60B |
Sector | Real Estate | Health |
52-Week High | $7.93 | $491.22 |
52-Week Low | $2.59 | $205.48 |
Enterprise Value | $738.32M | $27.56B |
Signals from Pluang's Aura AI — not financial advice
AIV trades at $2.605, down 0.57% on the day, with a bearish technical outlook showing 13 sell signals on moving averages. The stock presents a mixed fundamental picture with a strong 400% net income margin and 228% ROE for 2025, though revenue declined to $138M from $209M in 2024. Recent earnings show volatility with two beats and two misses in the last four quarters. The company announced a $1.30 dividend for H1-2026, payable in June 2026.
AIV offers value with a P/B ratio of 0.76 and positive cash flow generation, but faces challenges from declining revenue and inconsistent earnings performance. The bearish technical setup and mixed analyst sentiment (33% buy, 67% hold) suggest cautious optimism. Key risks include execution volatility and real estate sector headwinds, while the dividend provides income support.
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
Trailing returns across standard periods
Apartment Investment & Management Co is a self-managed real estate investment trust. It is focused on property development, redevelopment and various other value-creating investment strategies, targeting the U.S multifamily market. Its operating segments are Development and Redevelopment
Read more on AIV →Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →